ID: ALA4291435

Max Phase: Preclinical

Molecular Formula: C20H24N4O9

Molecular Weight: 464.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(-c2cn(CC(=O)N[C@H]3[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]3O)nn2)cc1

Standard InChI:  InChI=1S/C20H24N4O9/c1-32-11-4-2-10(3-5-11)12-7-24(23-22-12)8-16(28)21-17-13(26)6-15(20(30)31)33-19(17)18(29)14(27)9-25/h2-7,13-14,17-19,25-27,29H,8-9H2,1H3,(H,21,28)(H,30,31)/t13-,14+,17+,18+,19+/m0/s1

Standard InChI Key:  OUPACMPVCKGMEH-RMIBSVFLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 464.43

Molecular Weight (Monoisotopic): 464.1543

AlogP: -2.12

#Rotatable Bonds: 9

Polar Surface Area: 196.49

Molecular Species: ACID

HBA: 11

HBD: 6

#RO5 Violations: 2

HBA (Lipinski): 13

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: -4.52

CX Basic pKa:

CX LogP: -2.09

CX LogD: -5.56

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.24

Np Likeness Score: -0.07

References

1. Guo T, Héon-Roberts R, Zou C, Zheng R, Pshezhetsky AV, Cairo CW..  (2018)  Selective Inhibitors of Human Neuraminidase 1 (NEU1).,  61  (24): [PMID:30457869] [10.1021/acs.jmedchem.8b01411]

2.  (2018)  Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase, 

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data